



August 1, 2026

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051, Maharashtra.

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001, Maharashtra.

Symbol: STAR

Scrip Code: 532531

Dear Sirs,

Sub: Newspaper Advertisement – Unaudited Financial Results for the quarter ended June 30, 2026

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of newspaper advertisements published on August 1, 2026 in the 'Financial Express' (English newspaper) and 'Lokmat' (Marathi newspaper), providing extract of Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

These are also being made available on the Company's website at www.strides.com

This is for your information and records.

Thanks & Regards,
For **Strides Pharma Science Limited**,

MANJULA
RAMAMURTHY

Digitally signed by
MANJULA RAMAMURTHY
Date: 2026.08.01 16:21:48
+05'30'

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No.: A30515

Encl. as above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com



SMS PHARMACEUTICALS LIMITED
CIN :L24239TG1987PLC008066
Registered office: 8th Floor, Trendset Jayabheri Connect, Kondapur, Serilingampally, Ranga Reddy Dist., Hyderabad- 500084, Telangana, India
Phone No: 040-69859999 | Website: www.smspharma.com | email: complianceofficer@smspharma.com

Extract of Financial Results for the Quarter Ended 30th June, 2026

Sl. No.	Particulars	Standalone				Consolidated			
		Quarter Ended	Quarter Ended	Quarter Ended	Year Ended	Quarter Ended	Quarter Ended	Quarter Ended	Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026	30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from Operations (net)	20,870.93	24,052.19	19,664.02	89,522.48	20,870.93	24,052.19	19,664.02	89,522.48
2	Profit from Ordinary Activities before Tax	2,814.42	2,704.55	2,386.18	11,627.13	2,720.50	2,706.68	2,436.90	11,663.76
3	Profit from Ordinary Activities after Tax (after Extraordinary Items)	2,113.26	2,092.08	1,820.75	8,760.93	2,090.90	3,271.39	2,049.05	10,198.91
4	Total Comprehensive Income for the quarter (comprising profit/Loss) for the quarter (after tax) and other comprehensive items	2,105.78	2,115.52	1,811.31	8,764.24	2,084.40	3,299.64	2,040.25	10,208.97
5	Equity Share Capital (Face value of share: ₹ 1/- each)	936.52	936.52	886.52	936.52	936.52	936.52	886.52	936.52
6	Reserves (excluding Revaluation Reserve as per Balance Sheet) ₹ 1/- each	-	-	-	79,542.17	-	-	-	77,644.36
7	Earnings per share (before extraordinary items - (Not annualized)								
	a) Basic/Diluted (in ₹)	2.26	2.29	2.05	9.58	2.23	3.58	2.31	11.15

Notes:
1. The above Standalone and consolidated Financial Results have been reviewed and recommended by the Audit Committee in its meeting held on 31.07.2026 and approved by the Board of Directors in their meeting held on 31.07.2026 and Statutory Auditors of the Company have carried out a Limited Review.
2. These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed Under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above is an extract of detailed format of quarterly / annual financial results filed with the stock exchanges under regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of quarterly / annual financial results are available on the website of the Stock Exchanges of BSE www.bseindia.com (ID: 532815) or NSE www.nseindia.com (SMPHARMA) and companies website www.smspharma.com.



By order of the Board
for SMS Pharmaceuticals Limited
Sd/-
Ramesh Babu Potluri
(DIN: 00166381)
Chairman and Managing Director

Place: Hyderabad
Date: 31.07.2026



GOVERNMENT OF TAMIL NADU
PROJECT DEVELOPMENT GRANT FUND (PDGF)
INVITATION FOR PROPOSAL (IFP)
Consulting services
Ref: PDGF/GoTN/Tambaram WS DPR, TA & Erode WS TA/2026

1. Project Development Grant Fund (PDGF) intends to appoint a firm to provide the following consulting services as detailed in the table below:

Description of Services	Estimated Value incl. GST in Rs.	EMD in Rs.	e-Tender Submission last date	e-Tender Opening date
Updating the Water Supply DPR for entire Tambaram City Municipal Corporation (including Village Panchayats) area on 24*7 basis, Providing Transaction Advisory Services for the Phase I area of 24*7 Water Supply in Tambaram Added areas (Sembakkam, Madambakkam, Chittalapakkam, Tiruneermalai, Perungalthur and Peerkamakanai) on PPP mode and Providing Transaction Advisory Services for the 24*7 Water Supply in Erode City Municipal Corporation on PPP mode	2,00,00,000/-	2,00,000/-	31-08-2026 upto 11.00 hrs.	31-08-2026 after 12.30 hrs.

2. The assignment is open to all eligible firms. The Request for Proposals (RFP) may be downloaded and used free of cost from the website viz. <https://tntenders.gov.in> Proposals complete in all aspects must be submitted online through the Tamil Nadu e-tender website, as specified in the RFP.
3. A pre-proposal conference will be held on 07.08.2026 at 11.00 am in the office of TNUISL, to clarify queries, if any as stated in the RFP.
4. Any Clarifications, Minutes of Pre-proposal meeting, Extension of time and Addendum & Corrigendum issued will be uploaded only in the Tamil Nadu e-tender website. Other details are available in the RFP.
Managing Director,
TNUISL Fund Manager of PDGF

DIPR/2421/TENDER/2026



Strides Pharma Science Limited
CIN : L24230MH1990PLC057062
Registered Office: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703. Tel No.: +91 22 2789 2924/3199
Corporate Office: 'Strides House', Bilekahalli, Bannerghatta Road, Bengaluru - 560 076. Tel No.: +91 80 6784 0000
Website: www.strides.com; Email ID: investors@strides.com

Extract of the consolidated unaudited financial results for the quarter ended June 30, 2026

Particulars	Consolidated			
	3 Months ended June 30, 2026	Preceding 3 Months ended March 31, 2026	Corresponding 3 Months ended in the previous year June 30, 2025	Previous year ended March 31, 2026
	UNAUDITED	AUDITED	UNAUDITED	AUDITED
	Rs. in Million	Rs. in Million	Rs. in Million	Rs. in Million
Continuing operations				
Revenue from operations	12,654.07	13,234.70	11,197.36	48,586.83
Net Profit from ordinary activities before Exceptional Items and tax (*)	1,377.04	1,530.07	1,303.11	6,950.60
Net Profit/ (Loss) from ordinary activities before tax from continuing operations	1,996.16	1,480.51	1,220.43	6,686.86
Net Profit/ (Loss) from ordinary activities after tax from continuing operations	1,654.93	1,292.81	1,055.93	5,745.20
Profit/(loss) after tax from discontinued operations	-	-	-	-
Total comprehensive income for the period	1,944.10	1,489.85	1,442.82	6,185.43
Equity share capital	921.73	921.73	921.63	921.73
Other equity	32,005.40	30,153.92	25,978.63	30,153.92
Earnings per equity share (for total operations) (face value of Rs. 10/- each) - not annualised				
(a) Basic EPS (Rs.)	17.02	13.77	10.81	60.34
(b) Diluted EPS (Rs.)	17.02	13.77	10.81	60.34

(*) The Company did not have Extra-ordinary items for the given periods.
Information on Standalone Results :-

Particulars	3 Months ended June 30, 2026	Preceding 3 Months ended March 31, 2026	Corresponding 3 Months ended in the previous year June 30, 2025	Previous year ended March 31, 2026
	UNAUDITED	AUDITED	UNAUDITED	AUDITED
	Rs. in Million	Rs. in Million	Rs. in Million	Rs. in Million
	Rs. in Million	Rs. in Million	Rs. in Million	Rs. in Million
Total Revenue from continuing operations	5,841.23	6,097.05	5,003.74	23,031.98
Profit/(loss) before Tax from continuing operations	847.58	265.08	164.03	2,031.01
Profit/(loss) after Tax from continuing operations	729.28	163.53	133.47	1,836.35
Profit/(loss) before tax from discontinued operations	-	-	-	-
Profit/(loss) after tax from discontinued operations	-	-	-	-

Notes: The above is an extract of detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites viz., www.nseindia.com & www.bseindia.com and on the Company's website www.strides.com. The same can also be accessed by scanning the QR Code provided below:



For and on behalf of the Board
Sd/-
Badree Komandur
Managing Director and Group CEO
Bengaluru, July 31, 2026



Clean Max Enviro Energy Solutions Limited
(formerly known as Clean Max Enviro Energy Solutions Private Limited)
CIN : L30090MH2010PLC208425
Registered and Head Office Address: 4th Floor, The International, 16 Maharsi Karve Road, New Marine Lines, Cross Road No.1, Churchgate, Mumbai 400 020 Maharashtra, India | Telephone: +91 22 6252 0000
Email id: info@cleanmax.com | Website: www.cleanmax.com

Extract of consolidated financial results for the quarter ended 30th June, 2026

S No.	Particulars	Quarter ended		Year Ended	
		30th June, 2026	31st March, 2026	30th June, 2025	31st March, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		(In Rs. Million)	(In Rs. Million)	(In Rs. Million)	(In Rs. Million)
1	Total Income from Operations	8,741.02	6,395.87	4,112.39	20,752.14
2	Net Profit / (Loss) for the period (before Tax and Exceptional Items)	939.96	752.55	(295.39)	1,349.81
3	Net Profit / (Loss) for the period before tax (after Exceptional Items)	939.96	752.55	(295.39)	1,349.81
4	Net Profit / (Loss) for the period after tax (after Exceptional Items)	551.74	453.96	(165.97)	855.77
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	849.14	3,691.04	93.21	5,195.21
6	Paid up Equity Share Capital	117.22	117.08	50.72	117.08
7	Other Equity (Reserves)	47,097.30	46,265.58	26,500.08	46,265.58
8	Net worth	47,214.52	46,382.66	26,550.80	46,382.66
9	Outstanding Debt	1,38,339.51	1,24,003.38	89,088.29	1,24,003.38
10	Debt Equity Ratio (In times)	2.37	2.25	2.64	2.25
11	Earnings Per Share (of Re. 1/-each)				
	1. Basic (In Rs.):	4.14	5.31	(1.40)	9.10
	2. Diluted (In Rs.):	4.11	5.02	(1.35)	8.96
12	Debt Redemption Reserve	400.00	999.00	599.00	999.00
13	Debt Service Coverage Ratio (In times)	1.42	2.47	0.98	1.26
14	Interest Service Coverage Ratio (In times)	2.28	2.05	1.70	1.87

Extract of standalone financial results for the quarter ended 30th June, 2026

S No.	Particulars	Quarter ended		Year Ended	
		30th June, 2026	31st March, 2026	30th June, 2025	31st March, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		(In Rs. Million)	(In Rs. Million)	(In Rs. Million)	(In Rs. Million)
1	Total Income from Operations	22,972.75	20,071.81	11,896.55	63,573.12
2	Net Profit for the period (before Tax and Exceptional Items)	4,682.17	1,886.93	1,743.26	10,390.65
3	Net Profit for the period before tax (after Exceptional Items)	4,682.17	1,886.93	1,743.26	10,390.65
4	Net Profit for the period after tax (after Exceptional Items)	3,501.99	1,244.94	1,335.45	7,673.49
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	3,500.82	1,245.97	1,335.29	7,668.63
6	Paid up Equity Share Capital	117.22	117.08	50.72	117.08
7	Other Equity (Reserves)	59,977.19	56,361.53	35,381.58	56,361.53
8	Net worth	60,094.41	56,478.61	35,432.30	56,478.61
9	Outstanding Debt	16,655.44	21,501.99	18,000.72	21,501.99
10	Debt Equity Ratio (In times)	0.28	0.38	0.51	0.38
11	Earnings Per Share (of Re. 1/-each)				
	1. Basic (In Rs.):	29.90	11.93	13.16	74.17
	2. Diluted (In Rs.):	29.68	11.29	12.73	73.05
12	Debt Redemption Reserve	400.00	999.00	599.00	999.00
13	Debt Service Coverage Ratio (In times)	11.20	4.77	4.36	3.56
14	Interest Service Coverage Ratio (In times)	16.72	5.63	5.49	6.90

Notes:
1) The Board of Directors of the Company at its meeting held on 31 July 2026, approved standalone and consolidated unaudited financial results for the quarter ended June 2026.
2) The above is an extract of the consolidated/standalone financial results for the quarter ended 30th June, 2026. The full format of the consolidated/standalone financial results have been filed with the stock exchanges under Regulation 33 and 52 read with regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and is available on the website of the Company (<https://www.cleanmax.com/shareholder-information/information-to-stock-exchange>), the BSE Limited (www.bseindia.com) and the National Stock Exchange of India Ltd. (www.nseindia.com)
3) For the other line items referred in regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the BSE Limited, the National Stock Exchange of India Ltd. and can be accessed on the URL (www.bseindia.com), (www.nseindia.com) and on the website of the Company at <https://www.cleanmax.com/>.



For and on behalf of the Board of Directors of
Clean Max Enviro Energy Solutions Limited
(formerly known as
Clean Max Enviro Energy Solutions Private Limited)
Sd/-
Kuldeep Jain
Managing Director
DIN: 02683041

Place: Mumbai
Date: 31st July, 2026



ANKA INDIA LIMITED
CIN: L74900HR1994PLC033268
Regd. off.: Plot No. 271, Udyog Vihar, Phase-IV, Sector-18, Palam Road, Gurugram, Palam Road, Haryana, India, 122015
Email: response@ankaindia.com, Phone: +91-9355511187, website: <https://www.ankaindia.com/>

EXTRACT OF UN-AUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

Particulars	(Rs. In Lakh except EPS data)			
	STANDALONE		CONSOLIDATED	
	Quarter ended	Year Ended	Quarter ended	Year Ended
	30-Jun-26 (Un-Audited)	31-Mar-26 (Audited)	30-Jun-26 (Un-Audited)	31-Mar-26 (Audited)
Total income from operations	105.00	-	276.46	589.05
Net Profit/(Loss) before tax and share of (Loss)/profit in associates & Joint ventures	(0.91)	(20.18)	8.23	1.80
Net Profit/(Loss) for the period after tax and exceptional items	0.40	(20.18)	5.20	(0.92)
Total Comprehensive (loss) / Income for the period	0.40	(20.18)	5.20	2.95
Paid up Equity Capital (Face value of Rs. 10/- each)	515.42	233.34	443.68	395.36
Reserve excluding revaluation reserves	-	-	-	-
(As per last audited Balance Sheet)				
Earning Per Share (of Rs.10/- each) (not annualised)				
Basic	0.001	(0.09)	(0.01)	(0.00)
Diluted	0.001	(0.09)	(0.01)	(0.00)

Notes:
1. The above un-audited Standalone and Consolidated quarterly Financial results, prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting practices and policies to the extent applicable, were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on July 30, 2026 and are in compliance with the disclosure requirements of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
2. The above is an extract of the detailed format of the Un-audited Quarterly Financial Results for the quarter ended June 30, 2026, filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The Statutory Auditors of the Company have expressed a Qualified Opinion on the aforesaid financial results. The full format of the Financial Results, together with the Limited Review Report containing the Qualified Opinion, is available on the website of the Company (<https://www.ankaindia.com>) and on the website of BSE Limited (www.bseindia.com). The same can be accessed by scanning the QR Code provided below.
3. The Company is operating in only one segment, hence segment reporting is not given
4. Figures wherever required are regrouped/rearranged



By order of the Board
For Anka India Limited
Sd/-
Spark Sood
(Managing Director)
DIN:11416018

Date:- 30/07/2026
Place:- Gurugram



CONCORD BIOTECH LIMITED
B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat || Phone No. : +91-79-68138700
Fax : +91-79-68138725 || CIN : L24230GJ1984PLC007440 || Email Id : complianceofficer@concordbiotech.com || Website : www.concordbiotech.com
Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India || Phone No. : +91-2714-222804, 398200 || Fax : +91-2714-222504

STATEMENT OF STANDALONE / CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED ON JUNE 30, 2026 (Rs. In lakhs except per share data)

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter ended	Quarter ended	Quarter ended	Year ended	Quarter ended	Quarter ended	Quarter ended	Year ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026	30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from Operations	26,051.71	32,589.20	20,398.76	105,507.10	25,748.90	32,607.96	20,398.76	105,489.07
2	Net Profit / (Loss) for the period (before Tax Exceptional and / or Extraordinary items#)	8,220.96	11,837.76	5,723.95	35,470.72	7,834.31	11,407.54	5,873.18	34,792.26
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	8,220.96	11,837.76	5,723.95	35,143.18	7,834.31	11,407.54	5,873.18	34,464.72
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	6,119.37	9,002.21	4,256.55	26,326.67	5,769.69	8,846.69	4,405.78	25,922.91
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	7,824.64	10,363.55	3,974.67	31,904.48	7,475.83	10,173.02	4,123.90	31,447.27
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	200,929.01	-	-	-	200,659.97
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations- Not Annualised)								
	1) Basic	5.85	8.60	4.07	25.17	5.52	8.46	4.21	24.78
	2) Diluted	5.85	8.60	4.07	25.17	5.52	8.46	4.21	24.78

Notes:
(a) The above is an extract of the detailed format of unaudited Quarterly Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com.
(b) # - Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS/AS Rules, whichever is applicable.
(c) The above Unaudited Quarterly Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on July 31, 2026

For and on behalf of Board of Director of Concord Biotech Limited
Sudhir Vaid
Chairman & Managing Director - DIN : 00055967

Place : Ahmedabad
Date : July 31, 2026



